Doxorubicin in lymphoma: association between pharmacokinetic variability and clinical response.
Despite many years of clinical use in Hodgkin lymphoma, no previous studies have evaluated the relationship between doxorubicin pharmacokinetics and clinical response. In a pilot study, we associated the area under the curve of doxorubicin with successful remission. Patients with successful remission (n = 14) had a trend toward a higher median area under the curve than those who failed remission (n = 4; 36,390 versus 19,350 ng/mL x minute, P = 0.08, respectively). Median peak serum concentrations were 73 ng/mL among failures and 280 ng/mL in those who achieved remission (P = 0.06). The 2 groups did not differ regarding demographic and clinical parameters or doxorubicin dose. If corroborated by further studies, therapeutic drug monitoring of doxorubicin may be warranted in patients with Hodgkin lymphoma.
Elis
Avishay
A
Department of Medicine A, Meir Medical Center Kefar Saba, Israel. avishayel@clalit.org.il
Lishner
Michael
M
Walker
Scott
S
Atias
Dina
D
Korenberg
Avraham
A
Koren
Gideon
G
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D015331:Cohort Studies; D004317:Doxorubicin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016903:Drug Monitoring; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome; D055815:Young Adult
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin